Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Evaluating the Therapeutic Success of Keloids Treated With Cryotherapy and Intralesional Corticosteroids Using Noninvasive Objective Measures.

Schwaiger H, Reinholz M, Poetschke J, Ruzicka T, Gauglitz G.

Dermatol Surg. 2018 May;44(5):635-644. doi: 10.1097/DSS.0000000000001427.

PMID:
29701618
2.

Dermocosmetics for Use in Rosacea: Guideline of the Society for Dermopharmacy.

Kresken J, Kindl U, Wigger-Alberti W, Clanner-Engelshofen BM, Reinholz M.

Skin Pharmacol Physiol. 2018;31(3):147-154. doi: 10.1159/000486688. Epub 2018 Mar 29.

3.

[Paraneoplasms of the skin].

Gießen-Jung C, Wollenberg A, Reinholz M.

Internist (Berl). 2018 Feb;59(2):134-144. doi: 10.1007/s00108-017-0372-3. Review. German.

PMID:
29322218
4.

Frontal Fibrosing Alopecia: A Retrospective Analysis of 72 Patients from a German Academic Center.

Heppt MV, Letulé V, Laniauskaite I, Reinholz M, Tietze JK, Wolff H, Ruzicka T, Sattler EC.

Facial Plast Surg. 2018 Feb;34(1):88-94. doi: 10.1055/s-0037-1615281. Epub 2017 Dec 26.

PMID:
29278862
5.

Objective evaluation of the efficacy of a non-ablative fractional 1565 nm laser for the treatment of deliberate self-harm scars.

Guertler A, Reinholz M, Poetschke J, Steckmeier S, Schwaiger H, Gauglitz GG.

Lasers Med Sci. 2018 Feb;33(2):241-250. doi: 10.1007/s10103-017-2348-x. Epub 2017 Oct 27.

PMID:
29080008
6.

IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.

Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA.

Clin Cancer Res. 2017 Aug 1;23(15):4203-4211. doi: 10.1158/1078-0432.CCR-15-0574. Epub 2017 May 22.

PMID:
28533226
7.

Ultrapulsed fractional ablative carbon dioxide laser treatment of hypertrophic burn scars: evaluation of an in-patient controlled, standardized treatment approach.

Poetschke J, Dornseifer U, Clementoni MT, Reinholz M, Schwaiger H, Steckmeier S, Ruzicka T, Gauglitz GG.

Lasers Med Sci. 2017 Jul;32(5):1031-1040. doi: 10.1007/s10103-017-2204-z. Epub 2017 Apr 12.

PMID:
28401348
8.

The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab.

Tietze JK, Angelova D, Heppt MV, Reinholz M, Murphy WJ, Spannagl M, Ruzicka T, Berking C.

Eur J Cancer. 2017 Apr;75:268-279. doi: 10.1016/j.ejca.2016.12.031. Epub 2017 Feb 27.

PMID:
28242504
9.

EGFRI-induced papulopustular rosacea-like rash successfully treated with topical ivermectin.

Käser S, Ruini C, Ezmerli M, von Braunmühl T, Hartmann D, Ruzicka T, Reinholz M.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):e302-e304. doi: 10.1111/jdv.14089. Epub 2017 Jan 24. No abstract available.

PMID:
27988991
10.

Monitoring structural changes in Demodex mites under topical Ivermectin in rosacea by means of reflectance confocal microscopy: a case series.

Ruini C, Sattler E, Hartmann D, Reinholz M, Ruzicka T, von Braunmühl T.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):e299-e301. doi: 10.1111/jdv.14084. Epub 2017 Jan 3. No abstract available.

PMID:
27976437
11.

Pathogenese und Klinik der Rosazea als Schlüssel für eine symptomorientierte Therapie.

Reinholz M, Ruzicka T, Steinhoff M, Schaller M, Gieler U, Schöfer H, Homey B, Lehmann P, Luger TA.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:4-16. doi: 10.1111/ddg.13139_g. Review.

PMID:
27869378
12.

Pathogenesis and clinical presentation of rosacea as a key for a symptom-oriented therapy.

Reinholz M, Ruzicka T, Steinhoff M, Schaller M, Gieler U, Schöfer H, Homey B, Lehmann P, Luger TA.

J Dtsch Dermatol Ges. 2016 Dec;14 Suppl 6:4-15. doi: 10.1111/ddg.13139. Review.

PMID:
27869372
13.

Objective and subjective treatment evaluation of scars using optical coherence tomography, sonography, photography, and standardised questionnaires.

Reinholz M, Schwaiger H, Poetschke J, Epple A, Ruzicka T, Von Braunmühl T, Gauglitz GG.

Eur J Dermatol. 2016 Dec 1;26(6):599-608. doi: 10.1684/ejd.2016.2873.

PMID:
27762215
14.

DLQI and POSAS Scores in Keloid Patients.

Poetschke J, Reinholz M, Schwaiger H, Epple A, Gauglitz GG.

Facial Plast Surg. 2016 Jun;32(3):289-95. doi: 10.1055/s-0036-1583851. Epub 2016 Jun 1.

PMID:
27248027
15.

[Anogenital diseases caused by human papillomavirus - A modern pandemia].

Reinholz M, Hermans C, Ruzicka T, Dietrich A.

MMW Fortschr Med. 2016 Mar 17;158(5):64-6. doi: 10.1007/s15006-016-7946-1. Review. German. No abstract available.

PMID:
26979226
16.

Comparison of Two Kinds of Lasers in the Treatment of Acne Scars.

Reinholz M, Schwaiger H, Heppt MV, Poetschke J, Tietze J, Epple A, Ruzicka T, Kaudewitz P, Gauglitz GG.

Facial Plast Surg. 2015 Oct;31(5):523-31. doi: 10.1055/s-0035-1567814. Epub 2015 Nov 18.

PMID:
26579867
17.

Disease kinetics but not disease burden is relevant for survival in melanoma of unknown primary tumor.

Heppt MV, Tietze JK, Reinholz M, Rahimi F, Jung A, Kirchner T, Ruzicka T, Flaig MJ, Berking C.

Discov Med. 2015 Oct;20(110):231-7.

18.

Photoletter to the editor: Topical 0.5% brimonidine gel to camouflage redness of immature scars.

Reinholz M, Heppt M, Tietze JK, Ruzicka T, Gauglitz GG, Schauber J.

J Dermatol Case Rep. 2015 Sep 30;9(3):87-8. doi: 10.3315/jdcr.2015.1210. eCollection 2015 Sep 30.

19.

Current Strategies in the Treatment of Scars and Keloids.

Heppt MV, Breuninger H, Reinholz M, Feller-Heppt G, Ruzicka T, Gauglitz GG.

Facial Plast Surg. 2015 Aug;31(4):386-95. doi: 10.1055/s-0035-1563694. Epub 2015 Sep 15.

PMID:
26372714
20.

Human papillomavirus status, anal cytology and histopathological outcome in HIV-positive patients.

Dietrich A, Hermans C, Heppt MV, Ruzicka T, Schauber J, Reinholz M.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2011-8. doi: 10.1111/jdv.13205. Epub 2015 Aug 14.

PMID:
26274593
21.

[Fillers and associated side effects].

Heppt M, Hartmann D, Reinholz M, Feller-Heppt G, Ruzicka T, Gauglitz GG.

HNO. 2015 Jul;63(7):472-80. doi: 10.1007/s00106-015-0030-9. Review. German.

PMID:
26148563
22.

Transient memory impairment and transient global amnesia induced by photodynamic therapy.

Reinholz M, Heppt MV, Hoffmann FS, Lummel N, Ruzicka T, Lehmann P, Berking C.

Br J Dermatol. 2015 Nov;173(5):1258-62. doi: 10.1111/bjd.13985. Epub 2015 Oct 5.

PMID:
26122551
23.

The dermatology life quality index as a means to assess life quality in patients with different scar types.

Reinholz M, Poetschke J, Schwaiger H, Epple A, Ruzicka T, Gauglitz GG.

J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2112-9. doi: 10.1111/jdv.13135. Epub 2015 Apr 10.

PMID:
25866177
24.

Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population.

Heppt MV, Reinholz M, Tietze JK, Kerl K, French LE, Berking C, Kamarashev J.

Eur J Dermatol. 2015 Apr;25(2):127-32. doi: 10.1684/ejd.2014.2500.

PMID:
25787976
25.

Non-invasive diagnosis of sweat gland dysplasia using optical coherence tomography and reflectance confocal microscopy in a family with anhidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome).

Reinholz M, Gauglitz GG, Giehl K, Braun-Falco M, Schwaiger H, Schauber J, Ruzicka T, Berneburg M, von Braunmühl T.

J Eur Acad Dermatol Venereol. 2016 Apr;30(4):677-82. doi: 10.1111/jdv.13085. Epub 2015 Mar 9.

PMID:
25758344
26.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

27.

A case of cutaneous vegetating candidiasis in a patient with Keratitis-Ichthyosis-Deafness Syndrome.

Reinholz M, Hermans C, Dietrich A, Ruzicka T, Braun-Falco M.

J Eur Acad Dermatol Venereol. 2016 Mar;30(3):537-9. doi: 10.1111/jdv.12936. Epub 2015 Jan 20. No abstract available.

PMID:
25600479
28.

A peptide from a gastric pathogen for the treatment of acne.

Reinholz M.

Br J Dermatol. 2014 Dec;171(6):1291. doi: 10.1111/bjd.13458. No abstract available.

PMID:
25523255
29.

Photoallergic contact dermatitis due to treatment of pulmonary fibrosis with pirfenidone.

Reinholz M, Eder I, Przybilla B, Schauber J, Wollenberg A, Wulffen W, Goldscheider I, Varga R, Ruzicka T, Schaumann A, Ruëff F.

J Eur Acad Dermatol Venereol. 2016 Feb;30(2):370-1. doi: 10.1111/jdv.12794. Epub 2014 Oct 20. No abstract available.

PMID:
25327710
30.

Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: possible implications for rosacea.

Salzer S, Kresse S, Hirai Y, Koglin S, Reinholz M, Ruzicka T, Schauber J.

J Dermatol Sci. 2014 Dec;76(3):173-9. doi: 10.1016/j.jdermsci.2014.09.002. Epub 2014 Sep 28.

PMID:
25306296
31.

Lupus erythematosus-like skin eruption after vemurafenib therapy.

Reinholz M, Berking C, Hermans C, Ruzicka T, Braun-Falco M.

J Am Acad Dermatol. 2014 Oct;71(4):e159-60. doi: 10.1016/j.jaad.2014.07.006. No abstract available.

32.

Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study.

Ehmann L, Reinholz M, Maier T, Lang M, Wollenberg A.

Ann Dermatol. 2014 Aug;26(4):462-8. doi: 10.5021/ad.2014.26.4.462. Epub 2014 Jul 31.

33.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

34.

Darwin as a dermatologist.

Reinholz M, Ruzicka T.

JAMA Dermatol. 2014 Jun;150(6):600. doi: 10.1001/jamadermatol.2013.10439. No abstract available.

PMID:
24919515
35.

International study on inter-reader variability for circulating tumor cells in breast cancer.

Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K.

Breast Cancer Res. 2014 Apr 23;16(2):R43. doi: 10.1186/bcr3647.

36.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G.

Breast Cancer Res Treat. 2014 Feb;143(3):485-92. doi: 10.1007/s10549-013-2827-0. Epub 2014 Jan 7.

37.

Treatment of striae distensae using an ablative Erbium: YAG fractional laser versus a 585-nm pulsed-dye laser.

Gauglitz GG, Reinholz M, Kaudewitz P, Schauber J, Ruzicka T.

J Cosmet Laser Ther. 2014 Jun;16(3):117-9. doi: 10.3109/14764172.2013.854621. Epub 2013 Nov 18.

PMID:
24131065
38.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

39.

The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity.

Hartjen P, Höchst B, Heim D, von der Kammer H, Lucke J, Reinholz M, Baier A, Smeets R, Wege H, Borowski P, Schulze Zur Wiesch J.

Cell Mol Biol Lett. 2013 Sep;18(3):447-58. doi: 10.2478/s11658-013-0099-7. Epub 2013 Jul 27.

PMID:
23893289
40.

HPV16 activates the AIM2 inflammasome in keratinocytes.

Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, Kresse S, Ruzicka T, Schauber J.

Arch Dermatol Res. 2013 Oct;305(8):723-32. doi: 10.1007/s00403-013-1375-0. Epub 2013 Jun 14.

PMID:
23764897
41.

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.

42.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM.

J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.

43.

Rosacea - S1 guideline.

Reinholz M, Tietze JK, Kilian K, Schaller M, Schöfer H, Lehmann P, Zierhut M, Klövekorn W, Ruzicka T, Schauber J.

J Dtsch Dermatol Ges. 2013 Aug;11(8):768-80; 768-79. doi: 10.1111/ddg.12101. Epub 2013 May 6. English, German. No abstract available.

PMID:
23647643
44.

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ.

Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19.

45.

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.

Mahoney DW, Therneau TM, Anderson SK, Jen J, Kocher JP, Reinholz MM, Perez EA, Eckel-Passow JE.

BMC Res Notes. 2013 Jan 30;6:33. doi: 10.1186/1756-0500-6-33.

46.

[Vitamin D and innate immunity of the skin].

Reinholz M, Schauber J.

Dtsch Med Wochenschr. 2012 Nov;137(46):2385-9. doi: 10.1055/s-0032-1327277. Epub 2012 Nov 6. Review. German.

PMID:
23132159
47.

Honey bee (Apis mellifera) venom induces AIM2 inflammasome activation in human keratinocytes.

Dombrowski Y, Peric M, Koglin S, Kaymakanov N, Schmezer V, Reinholz M, Ruzicka T, Schauber J.

Allergy. 2012 Nov;67(11):1400-7. doi: 10.1111/all.12022. Epub 2012 Sep 13.

PMID:
22973906
48.

Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease.

Reinholz M, Ruzicka T, Schauber J.

Ann Dermatol. 2012 May;24(2):126-35. doi: 10.5021/ad.2012.24.2.126. Epub 2012 Apr 26.

49.

Vitamin D and its role in allergic disease.

Reinholz M, Ruzicka T, Schauber J.

Clin Exp Allergy. 2012 Jun;42(6):817-26. doi: 10.1111/j.1365-2222.2011.03923.x. Review.

PMID:
22192170
50.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B.

J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2.

Supplemental Content

Loading ...
Support Center